Research Article

You have full text access to this OnlineOpen article

Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: An open, observational, extension study of a three-month, randomized, placebo-controlled trial†

  1. J. Braun1,‡,*,
  2. J. Brandt2,‡,
  3. J. Listing3,
  4. A. Zink3,
  5. R. Alten4,
  6. G. Burmester5,
  7. W. Golder2,
  8. E. Gromnica-Ihle6,
  9. H. Kellner7,
  10. M. Schneider8,
  11. H. Sörensen9,
  12. H. Zeidler10,
  13. J. Reddig11,
  14. J. Sieper12

Article first published online: 1 AUG 2003

DOI: 10.1002/art.11104

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 48, Issue 8, pages 2224–2233, August 2003

Additional Information

How to Cite

Braun, J., Brandt, J., Listing, J., Zink, A., Alten, R., Burmester, G., Golder, W., Gromnica-Ihle, E., Kellner, H., Schneider, M., Sörensen, H., Zeidler, H., Reddig, J. and Sieper, J. (2003), Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: An open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis & Rheumatism, 48: 2224–2233. doi: 10.1002/art.11104

Author Information

  1. 1

    Benjamin Franklin Hospital, Free University, Berlin, Germany, and Rheumatology Medical Center Ruhrgebiet, Herne, Germany

  2. 2

    Benjamin Franklin Hospital, Free University, Berlin, Germany

  3. 3

    German Rheumatism Research Center, Berlin, Germany

  4. 4

    Schlosspark Clinic, Berlin, Germany

  5. 5

    Charité Hospital, Humboldt University, Berlin, Germany

  6. 6

    Berlin-Buch Hospital, Berlin, Germany

  7. 7

    Ludwig-Maximilians-University, Munich, Germany

  8. 8

    Heinrich-Heine-University, Düsseldorf, Germany

  9. 9

    Immanuel Hospital, Berlin, Germany

  10. 10

    Medical University, Hannover, Germany

  11. 11

    Essex Pharma, Munich, Germany

  12. 12

    Benjamin Franklin Hospital, Free University, Berlin, Germany, and German Rheumatism Research Center, Berlin, Germany

  1. ‡

    Drs. Braun and Brandt contributed equally to this work.

*Rheumazentrum Ruhrgebiet, Landgrafenstrasse 15, Herne 44652, Germany

  1. †

    Schering-Plough had no role in the study design or in the collection, analysis, or interpretation of the data. Essex Pharma, Munich, Germany, provided the study drug.

Publication History

  1. Issue published online: 1 AUG 2003
  2. Article first published online: 1 AUG 2003
  3. Manuscript Accepted: 14 APR 2003
  4. Manuscript Received: 14 FEB 2003

Funded by

  • Schering-Plough USA, Kenilworth, NJ

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (110K)

REFERENCES

  • 1
    Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, et al. Prevalence of spondylarthropathies in HLA–B27 positive and negative blood donors. Arthritis Rheum 1998; 41: 58–67.
    Direct Link:
  • 2
    Zink A, Braun J, Listing J, Wollenhaupt J, for the German Collaborative Arthritis Centers. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis: results from the German rheumatological database. J Rheumatol 2000; 27: 613–22.
  • 3
    Zink A, Listing J, Klindworth C, Zeidler H. The national database of the German Collaborative Arthritis Centres. I. Structure, aims, and patients. Ann Rheum Dis 2001; 60: 199–206.
  • 4
    Ward MM. Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res 1999; 12: 247–55.
    Direct Link:
  • 5
    Boonen A, Chorus A, Miedema H, van Der Heijde D, van Der Tempel H, van der Linden S. Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis 2001; 60: 353–8.
  • 6
    Boonen A, van der Heijde D, Landewé R, Spoorenberg A, Schouten H, Rutten-van Molken M, et al. Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis 2002; 61: 429–37.
  • 7
    Braun J, Sieper J. Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-α therapy and other novel approaches. Arthritis Res 2002; 4: 307–21.
  • 8
    Creemers MCW, Franssen MJAM, van De Putte LBA, Gribnau FWJ, van Riel PLCM. Methotrexate in severe ankylosing spondylitis: an open study. J Rheumatol 1995; 22: 1104–7.
  • 9
    Roychowdhury B, Bintley-Bagot S, Bulgen DY, Thompson RN, Tunn EJ, Moots RJ. Is methotrexate effective in ankylosing spondylitis? Rheumatology (Oxford). 2002; 41: 1330–2.
  • 10
    Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1999; 42: 2325–9.
    Direct Link:
  • 11
    Dougados M, van der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E, et al. Sulfasalazine in the treatment of spondylarthropathy: a randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995; 38: 618–27.
    Direct Link:
  • 12
    Braun J, Brandt J, Listing J, Zink A, Alten R, Krause A, et al. Treatment of active ankylosing spondylitis with infliximab: a double-blind placebo controlled multicenter trial. Lancet 2002; 359: 1187–93.
  • 13
    Brandt J, Haibel H, Sieper J, Reddig J, Braun J. Infliximab treatment of severe ankylosing spondylitis: one-year followup [letter]. Arthritis Rheum 2001; 44: 2936–7.
    Direct Link:
  • 14
    Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361–8.
  • 15
    Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286–91.
  • 16
    Van der Heijde D, Bellamy N, Calin A, Dougados M, Khan MA, van der Linden S. Preliminary core sets for end points in ankylosing spondylitis. J Rheumatol 1997; 24: 2225–9.
  • 17
    Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing Spondylitis Assessment Group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001; 44: 1876–86.
    Direct Link:
  • 18
    Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 2281–5.
  • 19
    Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS Metrology Index. J Rheumatol 1994; 21: 1694–8.
  • 20
    MacKay K, Mack C, Brophy S, Calin A. The Bath Ankylosing Spondylitis Radiology Index (BASRI): a new, validated approach to disease assessment. Arthritis Rheum 1998; 41: 2263–70.
    Direct Link:
  • 21
    Ware JE Jr, Sherbourne CD. The MOS 36-item Short-Form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473–83.
  • 22
    Medical Outcome Trust. How to score the SF-36 Health Survey. 2nd ed. Boston: Medical Outcome Trust; 1994.
  • 23
    Listing J, Schlittgen R. Tests if dropouts are missed at random. Biometric J 1988; 40: 929–35.
    Direct Link:
  • 24
    Braun J, Bollow M, Sieper J. Radiologic diagnosis and pathology of the spondyloarthropathies. Rheum Dis Clin North Am 1998; 24: 697–735.
  • 25
    Braun J, Baraliakos X, Golder W, Brandt J, Rudwaleit M, Listing J, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 2003; 48: 1126–36.
    Direct Link:
  • 26
    Brophy S, Pavy S, Lewis P, Taylor G, Bradbury L, Robertson D, et al. Inflammatory eye, skin, and bowel disease in spondyloarthritis: genetic, phenotypic, and environmental factors. J Rheumatol 2001; 28: 2667–73.
  • 27
    Rudwaleit M, Siegert S, Yin Z, Eick J, Thiel A, Radbruch A, et al. Low T cell production of TNFα and IFNγ in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. Ann Rheum Dis 2001; 60: 36–42.
  • 28
    Gonzalez S, Torre-Alonso JC, Martinez-Borra J, Fernandez Sanchez JA, Lopez-Vazquez A, Rodriguez Perez A, et al. TNF-238A promoter polymorphism contributes to susceptibility to ankylosing spondylitis in HLA-B27 negative patients. J Rheumatol 2001; 28: 1288–93.
  • 29
    Lipsky PE, van der Heijde DMFM, St. Clair EW, Furst DE, Breedveld FC, Kalden JR, et al, for the Anti–Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594–602.
  • 30
    Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541–9.
  • 31
    Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121: 1088–94.
  • 32
    Kavanaugh AF, Keenan GF, DeWoody K, Marstens P, Hendricks D, Clark J, et al. Long-term follow-up of patients treated with Remicade (infliximab) in clinical trials [abstract]. Arthritis Rheum 2001; 44 Suppl 9: S81.
  • 33
    Van den Bosch F, Kruithof E, De Vos M, De Keyser F, Mielants H. Crohn's disease associated with spondyloarthropathy: effect of TNF-α blockade with infliximab on articular symptoms. Lancet 2000; 356: 1821–2.
  • 34
    Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum 2001; 44: 2112–7.
    Direct Link:
  • 35
    Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis. Ann Rheum Dis 2003; 62: 74–6.
  • 36
    Baeten D, De Keyser F, Mielants H, Veys EM. Immune linkages between inflammatory bowel disease and spondyloarthropathies. Curr Opin Rheumatol 2002; 14: 342–7.
View Full Article (HTML) Get PDF (110K)